CBR1 Antikörper (AA 201-277) (Cy5.5)
Kurzübersicht für CBR1 Antikörper (AA 201-277) (Cy5.5) (ABIN5557359)
Target
Alle CBR1 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 201-277
-
Kreuzreaktivität
- Maus
-
Homologie
- Human,Rat
-
Aufreinigung
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human CBR1
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
-
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 -
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 μg/μL
-
Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
-
Konservierungsmittel
- ProClin
-
Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
-
Haltbarkeit
- 12 months
-
-
- CBR1 (Carbonyl Reductase 1 (CBR1))
-
Andere Bezeichnung
- CBR1
-
Hintergrund
-
Synonyms: Carbonyl reductase [NADPH] 1, CBR1, 15-hydroxyprostaglandin dehydrogenase [NADP(+)], NADPH-dependent carbonyl reductase 1, Prostaglandin 9-ketoreductase, Prostaglandin-E(2) 9-reductase (EC:1.1.1.189), Short chain dehydrogenase/reductase family 21C member 1, CBR, CRN, SDR21C1
Background: NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol. Can convert prostaglandin E2 to prostaglandin F2-alpha. Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S-nitrosoglutathione.
-
Gen-ID
- 873
-
UniProt
- P16152
Target
-